Relationship Between Hyperventilation Syndrome and SARS-CoV-2 Infection (Hypercovid)

September 6, 2022 updated by: Central Hospital, Nancy, France

A Cross-sectional Study : Is There a Relationship Between Hyperventilation Syndrome and History of Acute SARS-CoV-2 Infection?

Following an acute COVID-19 infection, many patients suffer from long lasting physical symptoms that may greatly impair quality of life. Persisting dyspnea and other functional respiratory complaints could evoke Hyperventilation Syndrome (HVS) as a putative contributor of the long-COVID presentation in COVID-19 survivors. We aimed to assess the possible relationship between a HVS and previous acute SARS-CoV-2 infection.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

2846

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Vandoeuvre les nancy, France, 54500
        • Centre Hospitalier Régional Universitaire de Nancy.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The inclusion criteria were age greater than 18 years old, with the ability to perform a pulmonary function test in our Lung Function and Exercise Testing Department. Eligible patients were able to read and speak French in order to correctly answer to the self-reported questionnaire. The exclusion criteria were incomplete questionnaire or inability to obtain an interpretable lung function assessment.

Description

Inclusion Criteria:

  • Read and speak French
  • Perform a pulmonary function test

Exclusion Criteria:

- incomplete questionnaire or inability to obtain an interpretable lung function assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Presence of Hyperventilation Syndrome (HVS+)
Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score > 23/64
Other: Nijmegen questionnaire score
We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
No presence of Hyperventilation Syndrome (HVS-).
Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score < 24/64
Other: Nijmegen questionnaire score
We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Assess the relationship between a hyperventilation syndrome and previous acute SARS-CoV-2 infection.
Time Frame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)

Secondary Outcome Measures

Outcome Measure
Time Frame
Assess the relationship between a hyperventilation syndrome and dyspnea
Time Frame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2021

Primary Completion (ACTUAL)

May 1, 2022

Study Completion (ACTUAL)

July 1, 2022

Study Registration Dates

First Submitted

February 3, 2022

First Submitted That Met QC Criteria

February 3, 2022

First Posted (ACTUAL)

February 4, 2022

Study Record Updates

Last Update Posted (ACTUAL)

September 7, 2022

Last Update Submitted That Met QC Criteria

September 6, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021PI224-203

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Nijmegen questionnaire score

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe